Liver Fibrosis

The most widely recognized liver condition is Liver fibrosis and it is the imbalance of decay and synthesis of the extra cellular matrix (ECM) and collagens caused by necrosis and liver cell inflammation. Fibrosis is a procedure when connective tissue begins to proliferate in the portal parts. In a normal liver, 5.5 mg to 6.5 mg of collagen can be found in each gram of liver tissue.

Cirrhotic liver contains over 8.0 mg of collagen in every gram of liver tissue. It can also be higher than 20 mg. Liver fibrosis can be categorized into viral hepatitis fibrosis, parasitic infection fibrosis, alcoholic fibrosis, biliary fibrosis, intoxication fibrosis, cardiogenic fibrosis, and metabolic fibrosis. Immunologically, liver fibrosis can be categorized into two forms .i.e. passive fibrosis and active fibrosis. Viral hepatitis fibrosis is the most common form of liver fibrosis and is usually caused by chronic hepatitis C, B, and D. According to PubMed and scientific journal research, around 500 million people are affected by hepatitis B and C virus. Infected people develop chronic hepatitis, which leads to fibrosis. Liver fibrosis can cause major complications, including liver failure, portal hypertension, and liver cancer. The risk of liver cancer is greatly increased once fibrosis develops. Liver cancer is among the top ten causes of death globally. High alcohol consumption, fatty liver (steatosis), and insulin resistance increase the risk of liver fibrosis.

When we talk about region, then the world wide liver fibrosis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for liver fibrosis drugs. In terms of revenue, the U.S. holds a major share of the liver fibrosis drugs market in North America. The market in Europe is expanding rapidly due to increase in the patient population in the region, especially in the U.K. and Germany. The market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to the growth of the market in Asia Pacific between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people in these countries.

    Related Conference of Liver Fibrosis

    October 29-30, 2018

    4th World Congress on Digestive & Metabolic Diseases

    | San Francisco, California, USA
    November 07-08, 2018

    World Summit on Liver Cirrhosis and Hepatitis

    Singapore
    December 17-18, 2018

    3rd World Liver Congress

    Abu Dhabi, UAE
    January 30-31, 2019

    16th World Congress on Gastroenterology & Therapeutics

    Bangkok, Thailand
    March 04-05, 2019

    20th World Congress on Gastroenterology

    Berlin, Germany
    June 17-18, 2019

    World Liver Conference 2019

    Columbus, Ohio, U.S.A
    July 08-09, 2019

    14th Euro-Global Gastroenterology Conference

    Zurich, Switzerland
    July 15-16, 2019

    7th International Conference on Hepatology

    Sydney, Australia
    October 14-15, 2019

    19th World Gastroenterologists Summit

    Sydney, Australia

    Liver Fibrosis Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in